Literature DB >> 20166126

Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.

Hannelore V Heemers1, Lucy J Schmidt, Emily Kidd, Kristin A Raclaw, Kevin M Regan, Donald J Tindall.   

Abstract

BACKGROUND: Deregulated androgen receptor (AR) action is critical for prostate cancer (PCa) progression. Aberrant expression of AR-associated coregulators contributes to AR activity in PCa. The mechanisms underlying coregulator expression in PCa are under intense investigation as they may lead to alternative means of targeting AR activity in PCa cells. We have recently shown that over 30% of coregulator expression in the PCa cell line LNCaP is subject to androgen regulation.
METHODS: Using multiple PCa cell lines as well as xenograft models, non-malignant prostate epithelial cell lines and androgen-responsive tissues derived from a male Wistar rat model system, we explored the effect of androgen stimulation and androgen deprivation on the expression of the core coactivators SRC1, SRC2, SRC3, CBP, and p300.
RESULTS: Androgen stimulation of model systems representing PCa led to a decrease in the expression of SRC1, SRC2, SRC3, CBP, and p300, whereas androgen deprivation induced the expression of these coactivators. In contrast, expression of these coregulators remained largely unaffected following changes in the androgenic milieu in AR-positive models representing non-malignant prostate cells and tissues.
CONCLUSIONS: Our data indicate differences in the regulation of coregulator expression between neoplastic and normal prostate cells. These findings emphasize the important potential of targeting the mechanisms regulating coregulator expression for therapeutic intervention in PCa.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166126      PMCID: PMC2875314          DOI: 10.1002/pros.21130

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

1.  LuCaP 35: a new model of prostate cancer progression to androgen independence.

Authors:  Eva Corey; Janna E Quinn; Kent R Buhler; Peter S Nelson; Jill A Macoska; Lawrence D True; Robert L Vessella
Journal:  Prostate       Date:  2003-06-01       Impact factor: 4.104

Review 2.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Authors:  Ivan V Litvinov; Angelo M De Marzo; John T Isaacs
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

3.  Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo.

Authors:  Hannelore Heemers; Frank Vanderhoydonc; Tania Roskams; Ishaiahu Shechter; Walter Heyns; Guido Verhoeven; Johannes V Swinnen
Journal:  Mol Cell Endocrinol       Date:  2003-07-31       Impact factor: 4.102

Review 4.  Androgen receptor (AR) coregulators: an overview.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2002-04       Impact factor: 19.871

5.  Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development.

Authors:  Kalipso Halkidou; Vincent J Gnanapragasam; Piyush B Mehta; Ian R Logan; Mark E Brady; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson
Journal:  Oncogene       Date:  2003-04-24       Impact factor: 9.867

6.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

7.  The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.

Authors:  Martine Gehin; Manuel Mark; Christine Dennefeld; Andrée Dierich; Hinrich Gronemeyer; Pierre Chambon
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  p300 in prostate cancer proliferation and progression.

Authors:  Jose D Debes; Thomas J Sebo; Christine M Lohse; Linda M Murphy; De Anna L Haugen; Donald J Tindall
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

9.  Intermediate basal cells of the prostate: in vitro and in vivo characterization.

Authors:  Levi A Garraway; Douglas Lin; Sabina Signoretti; David Waltregny; James Dilks; Nandita Bhattacharya; Massimo Loda
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

10.  The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.

Authors:  Barbara Comuzzi; Leonidas Lambrinidis; Hermann Rogatsch; Sonia Godoy-Tundidor; Nikola Knezevic; Ivan Krhen; Zvonimir Marekovic; Georg Bartsch; Helmut Klocker; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more
  9 in total

1.  BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.

Authors:  Joanna K Lempiäinen; A B M Kaiser Manjur; Marjo Malinen; Kirsi Ketola; Einari A Niskanen; Jorma J Palvimo
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

2.  Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.

Authors:  Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2016-09-08       Impact factor: 1.738

3.  RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Authors:  Lucy J Schmidt; Kelly Duncan; Neelu Yadav; Kevin M Regan; Alissa R Verone; Christine M Lohse; Elena A Pop; Kristopher Attwood; Gregory Wilding; James L Mohler; Thomas J Sebo; Donald J Tindall; Hannelore V Heemers
Journal:  Mol Endocrinol       Date:  2012-03-28

4.  Mechanisms of the androgen receptor splicing in prostate cancer cells.

Authors:  L L Liu; N Xie; S Sun; S Plymate; E Mostaghel; X Dong
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

Review 5.  Androgen Signaling in Prostate Cancer.

Authors:  Charles Dai; Hannelore Heemers; Nima Sharifi
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

6.  FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.

Authors:  Simon Haile; Aaron Lal; Jae-Kyung Myung; Marianne D Sadar
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

Review 7.  Splice Variants of Androgen Receptor and Prostate Cancer.

Authors:  Orazio Caffo; Francesca Maines; Antonello Veccia; Stefania Kinspergher; Enzo Galligioni
Journal:  Oncol Rev       Date:  2016-05-30

Review 8.  The diverse roles of SPOP in prostate cancer and kidney cancer.

Authors:  Zhiwei Wang; Yizuo Song; Miaomiao Ye; Xiaoming Dai; Xueqiong Zhu; Wenyi Wei
Journal:  Nat Rev Urol       Date:  2020-04-30       Impact factor: 14.432

9.  P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.

Authors:  Xiaokun Gang; Yinhui Yang; Jian Zhong; Kui Jiang; Yunqian Pan; R Jeffrey Karnes; Jun Zhang; Wanhai Xu; Guixia Wang; Haojie Huang
Journal:  Oncotarget       Date:  2016-03-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.